NanoViricides, Inc. Announces New Herpes Keratitis Study

NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), announced that it has signed a pre-clinical study agreement for the evaluation of NanoViricides’ drug candidate for herpes keratitis of the eye. The study will be conducted by Thevac, LLC, a spin-off of the Louisiana State University (LSU), Baton Rouge, LA.

More: continued here

Filed under: Eye Health on May 18th, 2009